Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9518326 | 0.98 | MGAM (0.34) | MGAMGAASIMGAM2LDHA | |
| SCHEMBL4334244 | 0.89 | MGAM (0.46) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL2885490 | 0.83 | GAA (0.46) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL2587969 | 0.81 | ADRA2A (0.43) | EGLN1TSHRADRA2AADRA1AMAPT | |
| SCHEMBL9518327 | 0.79 | CA4 (0.35) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL28736793 | 0.78 | TSHR (0.50) | TSHRADRA2AADRA1AMAPTBLM | |
| SCHEMBL2724170 | 0.78 | DGKA (0.47) | TSHR | |
| SCHEMBL4849723 | 0.77 | MGAM (0.39) | MGAMGAASIMGAM2LDHA | |
| SCHEMBL12296672 | 0.77 | NAAA (0.50) | MGAMGAASIMGAM2ADRA2A | |
| SCHEMBL154678 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | GREENGENE BIOSCIENCES INC. | 2022-07-21 | — | — | US | disclosed |
| EP-3679041-B1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-8586594-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2117526-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-09-20 | — | — | US | disclosed |
| US-8202878-B2 | Type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease;Trans [4-(4-{3-[2-(1-adamantyl)-2-hydroxyethoxy]-1H-pyrazol-5-yl}phenyl)cyclohexyl]acetic acid | ABBOTT LABORATORIES (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2117526-A2 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2008067257-A2 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-0300657-B1 | 4-SUBSTITUTED 3-OXOBUTANOATE ESTER DERIVATIVES | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | disclosed |
| EP-0300657-A2 | 4-substituted 3-oxobutanoate ester derivatives | MERCK & CO. INC. (US) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | MGAM 427/4885GAA 152/4885SI 527/4885 |
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | ATR, RB1, ATRIP | MGAM 4144/4885GAA 2074/4885SI 4769/4885 |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | MGAM 427/4885GAA 142/4885SI 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.